Medication adherence among patients with advanced prostate cancer using oral therapies
| العنوان: | Medication adherence among patients with advanced prostate cancer using oral therapies |
|---|---|
| المؤلفون: | Isabelle Ghelerter, Marie-Hélène Lafeuille, Mike Durkin, Joyce LaMori, Patrick Lefebvre, Lorie Ellis, Carmine Rossi, Dominic Pilon, Xuehua Ke |
| المصدر: | Future Oncology. 18:231-243 |
| بيانات النشر: | Future Medicine Ltd, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Abiraterone Acetate, Administration, Oral, Antineoplastic Agents, Pharmacy, Drug Costs, Medication Adherence, Young Adult, chemistry.chemical_compound, Prostate cancer, Quality of life, Internal medicine, Nitriles, Phenylthiohydantoin, Health care, medicine, Humans, Enzalutamide, Longitudinal Studies, Aged, Neoplasm Staging, Retrospective Studies, Chemotherapy, business.industry, Apalutamide, Age Factors, Abiraterone acetate, Prostatic Neoplasms, General Medicine, Middle Aged, medicine.disease, Thiohydantoins, Oncology, chemistry, Benzamides, Quality of Life, business |
| الوصف: | Aims: In light of the extended overall survival and improved quality of life provided by advanced prostate cancer (PC) oral therapies, this study aimed to describe treatment adherence to advanced PC oral therapies and evaluate associated patient characteristics and subsequent healthcare resource utilization (HRU). Patients & methods: Patients with advanced PC initiating apalutamide, enzalutamide or abiraterone acetate were identified from administrative data (October 1, 2014–September 30, 2019). Adherence and persistence at six months postinitiation were used to evaluate patient factors and HRU. Results: Aged ≥75 years, Black race, chemotherapy use and higher pharmacy paid amounts were associated with poor adherence/persistence, which translated to higher HRU. Conclusions: Strategies to increase adherence and persistence may improve patient outcomes and associated HRU. |
| تدمد: | 1744-8301 1479-6694 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7f66048a336df7bc441c35b9e39aac1Test https://doi.org/10.2217/fon-2021-0992Test |
| رقم الانضمام: | edsair.doi.dedup.....d7f66048a336df7bc441c35b9e39aac1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17448301 14796694 |
|---|